BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Nozawa H, Oda E, Nakao K, Ishihara M, Ueda S, Yokochi T, Ogasawara K, Nakatsuru Y, Shimizu S, Ohira Y, Hioki K, Aizawa S, Ishikawa T, Katsuki M, Muto T, Taniguchi T, Tanaka N. Loss of transcription factor IRF-1 affects tumor susceptibility in mice carrying the Ha-ras transgene or nullizygosity for p53. Genes Dev 1999;13:1240-5. [PMID: 10346812 DOI: 10.1101/gad.13.10.1240] [Cited by in Crossref: 95] [Cited by in F6Publishing: 89] [Article Influence: 4.1] [Reference Citation Analysis]
Number Citing Articles
1 Rettino A, Clarke NM. Genome-wide Identification of IRF1 Binding Sites Reveals Extensive Occupancy at Cell Death Associated Genes. J Carcinog Mutagen 2013:S6-009. [PMID: 25893139 DOI: 10.4172/2157-2518.S6-009] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
2 Takaoka A, Tamura T, Taniguchi T. Interferon regulatory factor family of transcription factors and regulation of oncogenesis. Cancer Sci 2008;99:467-78. [PMID: 18190617 DOI: 10.1111/j.1349-7006.2007.00720.x] [Cited by in Crossref: 105] [Cited by in F6Publishing: 100] [Article Influence: 7.5] [Reference Citation Analysis]
3 Chen FF, Jiang G, Xu K, Zheng JN. Function and mechanism by which interferon regulatory factor-1 inhibits oncogenesis. Oncol Lett 2013;5:417-23. [PMID: 23420765 DOI: 10.3892/ol.2012.1051] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 2.9] [Reference Citation Analysis]
4 Ferbeyre G, de Stanchina E, Querido E, Baptiste N, Prives C, Lowe SW. PML is induced by oncogenic ras and promotes premature senescence. Genes Dev. 2000;14:2015-2027. [PMID: 10950866 DOI: 10.1101/gad.14.16.2015] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
5 Sgorbissa A, Tomasella A, Potu H, Manini I, Brancolini C. Type I IFNs signaling and apoptosis resistance in glioblastoma cells. Apoptosis 2011;16:1229-44. [PMID: 21858676 DOI: 10.1007/s10495-011-0639-4] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 2.7] [Reference Citation Analysis]
6 Yoshimoto T, Morishima N, Mizoguchi I, Shimizu M, Nagai H, Oniki S, Oka M, Nishigori C, Mizuguchi J. Antiproliferative activity of IL-27 on melanoma. J Immunol 2008;180:6527-35. [PMID: 18453571 DOI: 10.4049/jimmunol.180.10.6527] [Cited by in Crossref: 100] [Cited by in F6Publishing: 87] [Article Influence: 7.1] [Reference Citation Analysis]
7 Giorgio ED, Paluvai H, Picco R, Brancolini C. Genetic Programs Driving Oncogenic Transformation: Lessons from in Vitro Models. Int J Mol Sci 2019;20:E6283. [PMID: 31842516 DOI: 10.3390/ijms20246283] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
8 Moschonas A, Kouraki M, Knox PG, Thymiakou E, Kardassis D, Eliopoulos AG. CD40 induces antigen transporter and immunoproteasome gene expression in carcinomas via the coordinated action of NF-kappaB and of NF-kappaB-mediated de novo synthesis of IRF-1. Mol Cell Biol 2008;28:6208-22. [PMID: 18694960 DOI: 10.1128/MCB.00611-08] [Cited by in Crossref: 22] [Cited by in F6Publishing: 14] [Article Influence: 1.6] [Reference Citation Analysis]
9 Yanai H, Negishi H, Taniguchi T. The IRF family of transcription factors: Inception, impact and implications in oncogenesis. Oncoimmunology 2012;1:1376-86. [PMID: 23243601 DOI: 10.4161/onci.22475] [Cited by in Crossref: 125] [Cited by in F6Publishing: 111] [Article Influence: 125.0] [Reference Citation Analysis]
10 Frontini M, Vijayakumar M, Garvin A, Clarke N. A ChIP-chip approach reveals a novel role for transcription factor IRF1 in the DNA damage response. Nucleic Acids Res 2009;37:1073-85. [PMID: 19129219 DOI: 10.1093/nar/gkn1051] [Cited by in Crossref: 38] [Cited by in F6Publishing: 37] [Article Influence: 2.9] [Reference Citation Analysis]
11 Ozanne B, Mcgarry L, Spence H, Johnston I, Winnie J, Meagher L, Stapleton G. Transcriptional regulation of cell invasion. European Journal of Cancer 2000;36:1640-8. [DOI: 10.1016/s0959-8049(00)00175-1] [Cited by in Crossref: 93] [Cited by in F6Publishing: 38] [Article Influence: 4.2] [Reference Citation Analysis]
12 Liu J, Guan X, Ma X. Interferon Regulatory Factor 1 Is an Essential and Direct Transcriptional Activator for Interferon γ-induced RANTES/CCl5 Expression in Macrophages. Journal of Biological Chemistry 2005;280:24347-55. [DOI: 10.1074/jbc.m500973200] [Cited by in Crossref: 59] [Cited by in F6Publishing: 41] [Article Influence: 3.5] [Reference Citation Analysis]
13 Jarosinski KW, Whitney LW, Massa PT. Specific deficiency in nuclear factor-kappaB activation in neurons of the central nervous system. Lab Invest 2001;81:1275-88. [PMID: 11555675 DOI: 10.1038/labinvest.3780341] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 0.7] [Reference Citation Analysis]
14 Dornan D, Eckert M, Wallace M, Shimizu H, Ramsay E, Hupp TR, Ball KL. Interferon regulatory factor 1 binding to p300 stimulates DNA-dependent acetylation of p53. Mol Cell Biol 2004;24:10083-98. [PMID: 15509808 DOI: 10.1128/MCB.24.22.10083-10098.2004] [Cited by in Crossref: 57] [Cited by in F6Publishing: 33] [Article Influence: 3.2] [Reference Citation Analysis]
15 Saha B, Jyothi Prasanna S, Chandrasekar B, Nandi D. Gene modulation and immunoregulatory roles of interferon gamma. Cytokine 2010;50:1-14. [PMID: 20036577 DOI: 10.1016/j.cyto.2009.11.021] [Cited by in Crossref: 202] [Cited by in F6Publishing: 198] [Article Influence: 15.5] [Reference Citation Analysis]
16 Kalvakolanu DV. The GRIMs: a new interface between cell death regulation and interferon/retinoid induced growth suppression. Cytokine Growth Factor Rev. 2004;15:169-194. [PMID: 15110800 DOI: 10.1016/j.cytogfr.2004.01.002] [Cited by in Crossref: 46] [Cited by in F6Publishing: 44] [Article Influence: 2.6] [Reference Citation Analysis]
17 Yang L, Ding JL. MEK1/2 Inhibitors Unlock the Constrained Interferon Response in Macrophages Through IRF1 Signaling. Front Immunol 2019;10:2020. [PMID: 31507609 DOI: 10.3389/fimmu.2019.02020] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
18 Camicia R, Bachmann SB, Winkler HC, Beer M, Tinguely M, Haralambieva E, Hassa PO. BAL1/ARTD9 represses the anti-proliferative and pro-apoptotic IFNγ-STAT1-IRF1-53 axes in diffuse large B-cell lymphoma. Journal of Cell Science. [DOI: 10.1242/jcs.118174] [Cited by in Crossref: 36] [Cited by in F6Publishing: 32] [Article Influence: 4.0] [Reference Citation Analysis]
19 Collet B, Hovens GC, Mazzoni D, Hirono I, Aoki T, Secombes CJ. Cloning and expression analysis of rainbow trout Oncorhynchus mykiss interferon regulatory factor 1 and 2 (IRF-1 and IRF-2). Dev Comp Immunol 2003;27:111-26. [PMID: 12543125 DOI: 10.1016/s0145-305x(02)00072-1] [Cited by in Crossref: 81] [Cited by in F6Publishing: 7] [Article Influence: 4.3] [Reference Citation Analysis]
20 Pamment J, Ramsay E, Kelleher M, Dornan D, Ball KL. Regulation of the IRF-1 tumour modifier during the response to genotoxic stress involves an ATM-dependent signalling pathway. Oncogene 2002;21:7776-85. [PMID: 12420214 DOI: 10.1038/sj.onc.1205981] [Cited by in Crossref: 71] [Cited by in F6Publishing: 66] [Article Influence: 3.6] [Reference Citation Analysis]
21 Schlee M, Hölzel M, Bernard S, Mailhammer R, Schuhmacher M, Reschke J, Eick D, Marinkovic D, Wirth T, Rosenwald A. C-myc activation impairs the NF-kappaB and the interferon response: implications for the pathogenesis of Burkitt’s lymphoma. Int J Cancer. 2007;120:1387-1395. [PMID: 17211884 DOI: 10.1002/ijc.22372] [Cited by in Crossref: 60] [Cited by in F6Publishing: 54] [Article Influence: 4.0] [Reference Citation Analysis]
22 Blankenstein T, Qin Z. Chemical Carcinogens as Foreign Bodies and Some Pitfalls Regarding Cancer Immune Surveillance. Elsevier; 2003. pp. 179-207. [DOI: 10.1016/s0065-230x(03)90006-6] [Cited by in Crossref: 30] [Cited by in F6Publishing: 4] [Article Influence: 1.6] [Reference Citation Analysis]
23 Maratheftis CI, Bolaraki PE, Giannouli S, Kapsogeorgou EK, Moutsopoulos HM, Voulgarelis M. Aberrant alternative splicing of interferon regulatory factor-1 (IRF-1) in myelodysplastic hematopoietic progenitor cells. Leuk Res 2006;30:1177-86. [PMID: 16483648 DOI: 10.1016/j.leukres.2005.12.021] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 0.8] [Reference Citation Analysis]
24 Langlais D, Barreiro LB, Gros P. The macrophage IRF8/IRF1 regulome is required for protection against infections and is associated with chronic inflammation. J Exp Med 2016;213:585-603. [PMID: 27001747 DOI: 10.1084/jem.20151764] [Cited by in Crossref: 108] [Cited by in F6Publishing: 91] [Article Influence: 18.0] [Reference Citation Analysis]
25 Bouker KB, Skaar TC, Riggins RB, Harburger DS, Fernandez DR, Zwart A, Wang A, Clarke R. Interferon regulatory factor-1 (IRF-1) exhibits tumor suppressor activities in breast cancer associated with caspase activation and induction of apoptosis. Carcinogenesis 2005;26:1527-35. [DOI: 10.1093/carcin/bgi113] [Cited by in Crossref: 90] [Cited by in F6Publishing: 82] [Article Influence: 5.3] [Reference Citation Analysis]
26 Clarke N, Jimenez-Lara AM, Voltz E, Gronemeyer H. Tumor suppressor IRF-1 mediates retinoid and interferon anticancer signaling to death ligand TRAIL. EMBO J 2004;23:3051-60. [PMID: 15241475 DOI: 10.1038/sj.emboj.7600302] [Cited by in Crossref: 109] [Cited by in F6Publishing: 92] [Article Influence: 6.1] [Reference Citation Analysis]
27 Tanaka N, Taniguchi T. The interferon regulatory factors and oncogenesis. Semin Cancer Biol 2000;10:73-81. [PMID: 10936058 DOI: 10.1006/scbi.2000.0310] [Cited by in Crossref: 60] [Cited by in F6Publishing: 60] [Article Influence: 2.7] [Reference Citation Analysis]
28 Philip M, Rowley DA, Schreiber H. Inflammation as a tumor promoter in cancer induction. Semin Cancer Biol. 2004;14:433-439. [PMID: 15489136 DOI: 10.1016/j.semcancer.2004.06.006] [Cited by in Crossref: 388] [Cited by in F6Publishing: 351] [Article Influence: 22.8] [Reference Citation Analysis]
29 Kröger A, Köster M, Schroeder K, Hauser H, Mueller PP. Review: Activities of IRF-1. Journal of Interferon & Cytokine Research 2002;22:5-14. [DOI: 10.1089/107999002753452610] [Cited by in Crossref: 192] [Cited by in F6Publishing: 189] [Article Influence: 9.6] [Reference Citation Analysis]
30 Eckert M, Meek SE, Ball KL. A novel repressor domain is required for maximal growth inhibition by the IRF-1 tumor suppressor. J Biol Chem 2006;281:23092-102. [PMID: 16679314 DOI: 10.1074/jbc.M512589200] [Cited by in Crossref: 15] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
31 Weaver BK, Ando O, Kumar KP, Reich NC. Apoptosis is promoted by the dsRNA‐activated factor (DRAF1) during viral infection independent of the action of interferon or p53. FASEB j 2001;15:501-15. [DOI: 10.1096/fj.00-0222com] [Cited by in Crossref: 56] [Cited by in F6Publishing: 56] [Article Influence: 2.7] [Reference Citation Analysis]
32 Ohki R, Nemoto J, Murasawa H, Oda E, Inazawa J, Tanaka N, Taniguchi T. Reprimo, a new candidate mediator of the p53-mediated cell cycle arrest at the G2 phase. J Biol Chem. 2000;275:22627-22630. [PMID: 10930422 DOI: 10.1074/jbc.c000235200] [Cited by in Crossref: 126] [Cited by in F6Publishing: 62] [Article Influence: 5.7] [Reference Citation Analysis]
33 Bowie ML, Ibarra C, Seewalt VL. IRF-1 promotes apoptosis in p53-damaged basal-type human mammary epithelial cells: a model for early basal-type mammary carcinogenesis. Adv Exp Med Biol 2008;617:367-74. [PMID: 18497060 DOI: 10.1007/978-0-387-69080-3_35] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
34 Chen Y, Li J, Lu N, Shen X. Interferon regulatory factors: A key to tumour immunity. International Immunopharmacology 2017;49:1-5. [DOI: 10.1016/j.intimp.2017.05.010] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
35 Liu J, Guan X, Ma X. Regulation of IL-27 p28 gene expression in macrophages through MyD88- and interferon-gamma-mediated pathways. J Exp Med 2007;204:141-52. [PMID: 17227910 DOI: 10.1084/jem.20061440] [Cited by in Crossref: 127] [Cited by in F6Publishing: 121] [Article Influence: 8.5] [Reference Citation Analysis]
36 Crow MS, Lum KK, Sheng X, Song B, Cristea IM. Diverse mechanisms evolved by DNA viruses to inhibit early host defenses. Crit Rev Biochem Mol Biol 2016;51:452-81. [PMID: 27650455 DOI: 10.1080/10409238.2016.1226250] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 3.5] [Reference Citation Analysis]
37 Kular RK, Yehiely F, Kotlo KU, Cilensek ZM, Bedi R, Deiss LP. GAGE, an Antiapoptotic Protein Binds and Modulates the Expression of Nucleophosmin/B23 and Interferon Regulatory Factor 1. Journal of Interferon & Cytokine Research 2009;29:645-56. [DOI: 10.1089/jir.2008.0099] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 1.7] [Reference Citation Analysis]
38 Romeo G, Fiorucci G, Chiantore MV, Percario ZA, Vannucchi S, Affabris E. IRF-1 as a negative regulator of cell proliferation. J Interferon Cytokine Res 2002;22:39-47. [PMID: 11846974 DOI: 10.1089/107999002753452647] [Cited by in Crossref: 85] [Cited by in F6Publishing: 82] [Article Influence: 4.3] [Reference Citation Analysis]
39 Wang J, Li H, Xue B, Deng R, Huang X, Xu Y, Chen S, Tian R, Wang X, Xun Z, Sang M, Zhu H. IRF1 Promotes the Innate Immune Response to Viral Infection by Enhancing the Activation of IRF3. J Virol 2020;94:e01231-20. [PMID: 32878885 DOI: 10.1128/JVI.01231-20] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
40 Kirchhoff S, Oumard A, Nourbakhsh M, Levi BZ, Hauser H. Interplay between repressing and activating domains defines the transcriptional activity of IRF-1. Eur J Biochem 2000;267:6753-61. [PMID: 11082185 DOI: 10.1046/j.1432-1033.2000.01750.x] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 1.2] [Reference Citation Analysis]
41 Chen HM, Tanaka N, Mitani Y, Oda E, Nozawa H, Chen JZ, Yanai H, Negishi H, Choi MK, Iwasaki T, Yamamoto H, Taniguchi T, Takaoka A. Critical role for constitutive type I interferon signaling in the prevention of cellular transformation. Cancer Sci 2009;100:449-56. [PMID: 19076978 DOI: 10.1111/j.1349-7006.2008.01051.x] [Cited by in Crossref: 40] [Cited by in F6Publishing: 38] [Article Influence: 2.9] [Reference Citation Analysis]
42 Kim E, Park C, Park J, Um S. Functional dissection of the transactivation domain of interferon regulatory factor-1. Biochemical and Biophysical Research Communications 2003;304:253-9. [DOI: 10.1016/s0006-291x(03)00575-8] [Cited by in Crossref: 9] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
43 Takaoka A, Taniguchi T. New aspects of IFN-alpha/beta signalling in immunity, oncogenesis and bone metabolism. Cancer Science 2003;94:405-11. [DOI: 10.1111/j.1349-7006.2003.tb01455.x] [Cited by in Crossref: 61] [Cited by in F6Publishing: 52] [Article Influence: 3.2] [Reference Citation Analysis]
44 Feng H, Zhang YB, Gui JF, Lemon SM, Yamane D. Interferon regulatory factor 1 (IRF1) and anti-pathogen innate immune responses. PLoS Pathog 2021;17:e1009220. [PMID: 33476326 DOI: 10.1371/journal.ppat.1009220] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 9.0] [Reference Citation Analysis]
45 Liang J, Piao Y, Henry V, Tiao N, de Groot JF. Interferon-regulatory factor-1 (IRF1) regulates bevacizumab induced autophagy. Oncotarget 2015;6:31479-92. [PMID: 26362401 DOI: 10.18632/oncotarget.5491] [Cited by in Crossref: 17] [Cited by in F6Publishing: 20] [Article Influence: 2.8] [Reference Citation Analysis]
46 Liebermann DA, Hoffman B. Myeloid differentiation (MyD)/growth arrest DNA damage (GADD) genes in tumor suppression, immunity and inflammation. Leukemia. 2002;16:527-541. [PMID: 11960329 DOI: 10.1038/sj.leu.2402477] [Cited by in Crossref: 62] [Cited by in F6Publishing: 64] [Article Influence: 3.1] [Reference Citation Analysis]
47 Oritani K, Kanakura Y. IFN-zeta/ limitin: a member of type I IFN with mild lympho-myelosuppression. J Cell Mol Med 2005;9:244-54. [PMID: 15963247 DOI: 10.1111/j.1582-4934.2005.tb00353.x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
48 Chapman RS, Duff EK, Lourenco PC, Tonner E, Flint DJ, Clarke AR, Watson CJ. A novel role for IRF-1 as a suppressor of apoptosis. Oncogene 2000;19:6386-91. [PMID: 11175354 DOI: 10.1038/sj.onc.1204016] [Cited by in Crossref: 33] [Cited by in F6Publishing: 35] [Article Influence: 1.6] [Reference Citation Analysis]
49 Pavan S, Olivero M, Corà D, Di Renzo MF. IRF-1 expression is induced by cisplatin in ovarian cancer cells and limits drug effectiveness. European Journal of Cancer 2013;49:964-73. [DOI: 10.1016/j.ejca.2012.09.024] [Cited by in Crossref: 11] [Cited by in F6Publishing: 15] [Article Influence: 1.2] [Reference Citation Analysis]
50 Guimarães DP, Oliveira IM, de Moraes E, Paiva GR, Souza DM, Barnas C, Olmedo DB, Pinto CE, Faria PA, De Moura Gallo CV, Small IA, Ferreira CG, Hainaut P. Interferon-inducible guanylate binding protein (GBP)-2: a novel p53-regulated tumor marker in esophageal squamous cell carcinomas. Int J Cancer 2009;124:272-9. [PMID: 19003964 DOI: 10.1002/ijc.23944] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 1.8] [Reference Citation Analysis]
51 Sun Q, Peng J, Xia H. IFNγ pretreatment sensitizes human choriocarcinoma cells to etoposide-induced apoptosis. MHR: Basic science of reproductive medicine 2006;12:99-105. [DOI: 10.1093/molehr/gah250] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.6] [Reference Citation Analysis]
52 Fu L, Kettner NM. The circadian clock in cancer development and therapy. Prog Mol Biol Transl Sci 2013;119:221-82. [PMID: 23899600 DOI: 10.1016/B978-0-12-396971-2.00009-9] [Cited by in Crossref: 126] [Cited by in F6Publishing: 81] [Article Influence: 15.8] [Reference Citation Analysis]
53 Savitsky D, Tamura T, Yanai H, Taniguchi T. Regulation of immunity and oncogenesis by the IRF transcription factor family. Cancer Immunol Immunother 2010;59:489-510. [DOI: 10.1007/s00262-009-0804-6] [Cited by in Crossref: 192] [Cited by in F6Publishing: 186] [Article Influence: 16.0] [Reference Citation Analysis]
54 Zhang J, Qian X, Ning H, Yang J, Xiong H, Liu J. Activation of IL-27 p28 gene transcription by interferon regulatory factor 8 in cooperation with interferon regulatory factor 1. J Biol Chem 2010;285:21269-81. [PMID: 20435892 DOI: 10.1074/jbc.M110.100818] [Cited by in Crossref: 45] [Cited by in F6Publishing: 30] [Article Influence: 3.8] [Reference Citation Analysis]
55 Siegel CT, Schreiber K, Meredith SC, Beck-Engeser GB, Lancki DW, Lazarski CA, Fu YX, Rowley DA, Schreiber H. Enhanced growth of primary tumors in cancer-prone mice after immunization against the mutant region of an inherited oncoprotein. J Exp Med 2000;191:1945-56. [PMID: 10839809 DOI: 10.1084/jem.191.11.1945] [Cited by in Crossref: 44] [Cited by in F6Publishing: 39] [Article Influence: 2.0] [Reference Citation Analysis]
56 Riggins RB, Bouton AH, Liu MC, Clarke R. Antiestrogens, aromatase inhibitors, and apoptosis in breast cancer. Vitam Horm. 2005;71:201-237. [PMID: 16112269 DOI: 10.1016/s0083-6729(05)71007-4] [Cited by in Crossref: 59] [Cited by in F6Publishing: 43] [Article Influence: 3.5] [Reference Citation Analysis]
57 Andersen P, Pedersen MW, Woetmann A, Villingshøj M, Stockhausen M, Ødum N, Poulsen HS. EGFR induces expression of IRF-1 via STAT1 and STAT3 activation leading to growth arrest of human cancer cells: EGFR Mediated IRF-1 Expression Through STAT Activation. Int J Cancer 2008;122:342-9. [DOI: 10.1002/ijc.23109] [Cited by in Crossref: 36] [Cited by in F6Publishing: 33] [Article Influence: 2.4] [Reference Citation Analysis]
58 Lee S, Kim J, Lee H, Cho Y, Oh S, Kim Y, Jung C, Zhang W, Lee J. Interferon regulatory factor-1 (IRF-1) is a mediator for interferon-γ induced attenuation of telomerase activity and human telomerase reverse transcriptase (hTERT) expression. Oncogene 2003;22:381-91. [DOI: 10.1038/sj.onc.1206133] [Cited by in Crossref: 44] [Cited by in F6Publishing: 39] [Article Influence: 2.3] [Reference Citation Analysis]
59 Arockiaraj J, Easwvaran S, Vanaraja P, Singh A, Othman RY, Bhassu S. First report on interferon related developmental regulator-1 from Macrobrachium rosenbergii: Bioinformatic analysis and gene expression. Fish & Shellfish Immunology 2012;32:929-33. [DOI: 10.1016/j.fsi.2012.02.011] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
60 Ohsugi T, Yamaguchi K, Zhu C, Ikenoue T, Takane K, Shinozaki M, Tsurita G, Yano H, Furukawa Y. Anti-apoptotic effect by the suppression of IRF1 as a downstream of Wnt/β-catenin signaling in colorectal cancer cells. Oncogene 2019;38:6051-64. [PMID: 31292489 DOI: 10.1038/s41388-019-0856-9] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
61 Basler CF, García-Sastre A. Viruses and the type I interferon antiviral system: induction and evasion. Int Rev Immunol 2002;21:305-37. [PMID: 12486817 DOI: 10.1080/08830180213277] [Cited by in Crossref: 95] [Cited by in F6Publishing: 92] [Article Influence: 5.0] [Reference Citation Analysis]
62 Kalvakolanu DV. Alternate interferon signaling pathways. Pharmacol Ther 2003;100:1-29. [PMID: 14550502 DOI: 10.1016/s0163-7258(03)00070-6] [Cited by in Crossref: 68] [Cited by in F6Publishing: 24] [Article Influence: 3.8] [Reference Citation Analysis]
63 Schlee M, Schuhmacher M, Hölzel M, Laux G, Bornkamm GW. c-MYC impairs immunogenicity of human B cells. Adv Cancer Res 2007;97:167-88. [PMID: 17419945 DOI: 10.1016/S0065-230X(06)97007-9] [Cited by in Crossref: 20] [Cited by in F6Publishing: 14] [Article Influence: 1.5] [Reference Citation Analysis]
64 Yang PM, Hsieh YY, Du JL, Yen SC, Hung CF. Sequential Interferon β-Cisplatin Treatment Enhances the Surface Exposure of Calreticulin in Cancer Cells via an Interferon Regulatory Factor 1-Dependent Manner. Biomolecules 2020;10:E643. [PMID: 32326356 DOI: 10.3390/biom10040643] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
65 Leonova KI, Brodsky L, Lipchick B, Pal M, Novototskaya L, Chenchik AA, Sen GC, Komarova EA, Gudkov AV. p53 cooperates with DNA methylation and a suicidal interferon response to maintain epigenetic silencing of repeats and noncoding RNAs. Proc Natl Acad Sci U S A 2013;110:E89-98. [PMID: 23236145 DOI: 10.1073/pnas.1216922110] [Cited by in Crossref: 158] [Cited by in F6Publishing: 140] [Article Influence: 15.8] [Reference Citation Analysis]
66 Schreiber H, Wu TH, Nachman J, Rowley DA. Immunological enhancement of primary tumor development and its prevention. Semin Cancer Biol. 2000;10:351-357. [PMID: 11100883 DOI: 10.1006/scbi.2000.0331] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 1.2] [Reference Citation Analysis]
67 Arockiaraj J, Sathyamoorthi A, Kumaresan V, Palanisamy R, Chaurasia MK, Bhatt P, Gnanam AJ, Pasupuleti M, Arasu A. A murrel interferon regulatory factor-1: molecular characterization, gene expression and cell protection activity. Mol Biol Rep 2014;41:5299-309. [PMID: 24859976 DOI: 10.1007/s11033-014-3401-5] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.8] [Reference Citation Analysis]
68 Su ZZ, Sarkar D, Emdad L, Barral PM, Fisher PB. Central role of interferon regulatory factor-1 (IRF-1) in controlling retinoic acid inducible gene-I (RIG-I) expression. J Cell Physiol 2007;213:502-10. [PMID: 17516545 DOI: 10.1002/jcp.21128] [Cited by in Crossref: 45] [Cited by in F6Publishing: 48] [Article Influence: 3.2] [Reference Citation Analysis]
69 Jacobs SR, Damania B. The viral interferon regulatory factors of KSHV: immunosuppressors or oncogenes? Front Immunol 2011;2:19. [PMID: 22566809 DOI: 10.3389/fimmu.2011.00019] [Cited by in Crossref: 45] [Cited by in F6Publishing: 44] [Article Influence: 4.1] [Reference Citation Analysis]
70 Jiménez-Lara AM, Clarke N, Altucci L, Gronemeyer H. Retinoic-acid-induced apoptosis in leukemia cells. Trends Mol Med 2004;10:508-15. [PMID: 15464451 DOI: 10.1016/j.molmed.2004.08.006] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 1.6] [Reference Citation Analysis]
71 Somerville TDD, Xu Y, Wu XS, Maia-Silva D, Hur SK, de Almeida LMN, Preall JB, Koo PK, Vakoc CR. ZBED2 is an antagonist of interferon regulatory factor 1 and modifies cell identity in pancreatic cancer. Proc Natl Acad Sci U S A 2020;117:11471-82. [PMID: 32385160 DOI: 10.1073/pnas.1921484117] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 3.5] [Reference Citation Analysis]
72 Nordlander C, Behboudi A, Levan G, Levan KK. Allelic imbalance on chromosome 10 in rat endometrial adenocarcinomas. Cancer Genet Cytogenet 2005;156:158-66. [PMID: 15642397 DOI: 10.1016/j.cancergencyto.2004.05.001] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
73 Pion E, Narayan V, Eckert M, Ball KL. Role of the IRF-1 enhancer domain in signalling polyubiquitination and degradation. Cell Signal 2009;21:1479-87. [PMID: 19450680 DOI: 10.1016/j.cellsig.2009.05.004] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 1.6] [Reference Citation Analysis]
74 Nakagawa K, Yokosawa H. Degradation of transcription factor IRF-1 by the ubiquitin-proteasome pathway. The C-terminal region governs the protein stability. Eur J Biochem 2000;267:1680-6. [PMID: 10712599 DOI: 10.1046/j.1432-1327.2000.01163.x] [Cited by in Crossref: 65] [Cited by in F6Publishing: 68] [Article Influence: 3.0] [Reference Citation Analysis]
75 Eason DD, LeBron C, Coppola D, Moscinski LC, Livingston S, Sutton ET, Blanck G. Development of CD30+ lymphoproliferative disease in mice lacking interferon regulatory factor-1. Oncogene 2003;22:6166-76. [PMID: 13679855 DOI: 10.1038/sj.onc.1206563] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
76 Pikor LA, Bell JC, Diallo JS. Oncolytic Viruses: Exploiting Cancer's Deal with the Devil. Trends Cancer 2015;1:266-77. [PMID: 28741515 DOI: 10.1016/j.trecan.2015.10.004] [Cited by in Crossref: 43] [Cited by in F6Publishing: 37] [Article Influence: 6.1] [Reference Citation Analysis]
77 Stoltz KP, Jondle CN, Pulakanti K, Sylvester PA, Urrutia R, Rao S, Tarakanova VL. Tumor suppressor Interferon Regulatory Factor 1 selectively blocks expression of endogenous retrovirus. Virology 2019;526:52-60. [PMID: 30342302 DOI: 10.1016/j.virol.2018.10.003] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
78 Sato M, Taniguchi T, Tanaka N. The interferon system and interferon regulatory factor transcription factors – studies from gene knockout mice. Cytokine & Growth Factor Reviews 2001;12:133-42. [DOI: 10.1016/s1359-6101(00)00032-0] [Cited by in Crossref: 114] [Cited by in F6Publishing: 33] [Article Influence: 5.4] [Reference Citation Analysis]
79 Dou L, Liang H, Geller DA, Chen Y, Chen X. The regulation role of interferon regulatory factor-1 gene and clinical relevance. Human Immunology 2014;75:1110-4. [DOI: 10.1016/j.humimm.2014.09.015] [Cited by in Crossref: 33] [Cited by in F6Publishing: 34] [Article Influence: 4.1] [Reference Citation Analysis]
80 Mannick EE, Cote RL, Schurr JR, Krowicka HS, Sloop GD, Zapata-Velandia A, Correa H, Ruiz B, Horswell R, Lentz JJ, Byrne P, Gastanaduy MM, Hornick CA, Liu Z. Altered phenotype of dextran sulfate sodium colitis in interferon regulatory factor-1 knock-out mice. J Gastroenterol Hepatol 2005;20:371-80. [PMID: 15740479 DOI: 10.1111/j.1440-1746.2005.03573.x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 0.8] [Reference Citation Analysis]
81 Clarke R, Shajahan AN, Riggins RB, Cho Y, Crawford A, Xuan J, Wang Y, Zwart A, Nehra R, Liu MC. Gene network signaling in hormone responsiveness modifies apoptosis and autophagy in breast cancer cells. J Steroid Biochem Mol Biol 2009;114:8-20. [PMID: 19444933 DOI: 10.1016/j.jsbmb.2008.12.023] [Cited by in Crossref: 56] [Cited by in F6Publishing: 54] [Article Influence: 4.3] [Reference Citation Analysis]
82 Lou Y, Xia D, Yu M, Tong J, Jin J. Identification of an IRF-1 splicing transcript in APL cells sharing similar transactivation activity of the full length one. Gene 2017;605:108-13. [PMID: 28039033 DOI: 10.1016/j.gene.2016.12.029] [Reference Citation Analysis]
83 Alsamman K, El-Masry OS. Interferon regulatory factor 1 inactivation in human cancer. Biosci Rep 2018;38:BSR20171672. [PMID: 29599126 DOI: 10.1042/BSR20171672] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 6.3] [Reference Citation Analysis]
84 Zhao J, Chen C, Xiao JR, Wei HF, Zhou XH, Mao XX, Zhang WD, Qian R, Chen XL, He MQ, Yu XW, Zhao J. An Up-regulation of IRF-1 After a Spinal Cord Injury: Implications for Neuronal Apoptosis. J Mol Neurosci 2015;57:595-604. [PMID: 26342280 DOI: 10.1007/s12031-015-0642-2] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
85 Cavalli LR, Riggins RB, Wang A, Clarke R, Haddad BR. Frequent loss of heterozygosity at the interferon regulatory factor-1 gene locus in breast cancer. Breast Cancer Res Treat 2010;121:227-31. [PMID: 19697121 DOI: 10.1007/s10549-009-0509-8] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 1.7] [Reference Citation Analysis]
86 Mboko WP, Mounce BC, Emmer J, Darrah E, Patel SB, Tarakanova VL. Interferon regulatory factor 1 restricts gammaherpesvirus replication in primary immune cells. J Virol 2014;88:6993-7004. [PMID: 24719409 DOI: 10.1128/JVI.00638-14] [Cited by in Crossref: 35] [Cited by in F6Publishing: 25] [Article Influence: 4.4] [Reference Citation Analysis]
87 Mboko WP, Olteanu H, Ray A, Xin G, Darrah EJ, Kumar SN, Kulinski JM, Cui W, Dittel BN, Gauld SB, Tarakanova VL. Tumor Suppressor Interferon-Regulatory Factor 1 Counteracts the Germinal Center Reaction Driven by a Cancer-Associated Gammaherpesvirus. J Virol 2015;90:2818-29. [PMID: 26719266 DOI: 10.1128/JVI.02774-15] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
88 Tura BJ, Bunyan KE, Harrison DJ. The effect of IFNgamma on the hepatocyte: cell cycle and apoptosis. Int J Exp Pathol 2001;82:317-26. [PMID: 11846838 DOI: 10.1046/j.1365-2613.2001.00207.x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 0.6] [Reference Citation Analysis]
89 Kim E, Park J, Um S. Ubc9-mediated sumoylation leads to transcriptional repression of IRF-1. Biochemical and Biophysical Research Communications 2008;377:952-6. [DOI: 10.1016/j.bbrc.2008.10.092] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 0.9] [Reference Citation Analysis]